Oncology electronic health records: More than just an e-secretary
October 1st 2008Electronic health records can help oncology practices save money and work smarter. Then why has the adoption of e-technology been so frustratingly slow? A recent survey in the New England Journal of Medicine found that only 4% of physicians reported having a fully functional electronic health record (EHR) system; only 13% reported having a basic system (NEJM 359: 50-60, 2008).
Barrie Cassileth, an integrative medicine pioneer
October 1st 2008When you remodel an old bank building, you may wind up with your office in a vault, as did two staff members at the Bendheim Integrative Medicine Center, Memorial Sloan-Kettering Cancer Center’s outpatient facility for complementary services and therapies.
Will presidential candidates’ promises to cancer research be enough?
October 1st 2008During this election year, approximately 1.4 million U.S. residents will be diagnosed with cancer. For U.S. presidential hopefuls Sen. Barack Obama and Sen. John McCain, cancer has hit close to home. Sen. McCain, 72, has been treated several times for squamous cell carcinoma and malignant melanoma. Sen. Obama lost his grandfather to prostate cancer and his mother to ovarian cancer.
The surgeon who challenged the breast ca paradigm
September 1st 2008Bernard Fisher, MD received his medical degree in 1943 from the University of Pittsburgh School of Medicine. As a young doctor, he was torn between a life in the operating room and one in the research lab. His curiosity about the biology of the diseases that were being treated by surgery eventually led to his decision to combine those interests.
FDA cracks down on counterfeit cancer cure products
August 1st 2008There are a plethora of websites that hawk miracle cancer cures, luring consumers in with seductive testimonials of instant good health. To the average person, these sites are dubious at best. But for some cancer patients, the promise of an easy panacea veers on dangerous.
LaSalle Leffall: Often the ‘first,’ & never the last
August 1st 2008As a boy growing up in the Jim Crow South, LaSalle Leffall, Jr., MD, lifted himself above that era’s stifling segregation by embracing his father’s rock-solid credo: With a good education and hard work, combined with honesty and integrity, there are no boundaries.
Cancer drug pipeline is healthy, says head of oncologic drug approval for FDA
August 1st 2008The US Food and Drug Administration is often depicted as an obstructionist bureaucracy that inhibits the development of life-saving cancer drugs. But according to an FDA insider, the real story on drug approval has remained untold.
How to bill a referral: New patient or consultation?
August 1st 2008A common conundrum that community oncologists face in their practices is whether to bill a first encounter with a new patient referred by another physician as a consultation or as a new patient visit. Making the distinction may seem like splitting hairs, but the Centers for Medicare and Medicaid Services (CMS) has very specific billing criteria on this issue.
Coverage vs Cost-Cutting: A look Inside the Obama and McCain Healthcare Plans
July 1st 2008CHICAGO-This year’s roiling political contest took center stage at ASCO 2008 in a special session that reviewed the healthcare insurance reform proposals of Sen. John McCain and Sen. Barack Obama, the presumptive presidential nominees.
Who’s responsible for safety of outsourced drugs?
June 2nd 2008These are trying times at FDA. The agency has its hands full regulating pharmaceuticals produced in the United States: Now come the perils of globalization, which were dramatized by the recent heparin scandal. FDA contends that the adverse events and deaths associated with Baxter’s heparin products were caused by a contaminant deliberately introduced somewhere in China’s raw material supply. Chinese regulators quickly rebuffed FDA’s claim, asserting the problem was more likely caused by impurities introduced in the final US drug production process.
Dr. Kanti Rai, researcher and ‘doctor’s doctor’
June 1st 2008Kanti R. Rai, MD, was born in the sun-drenched city of Jodhpur, India, during the waning years of British colonial rule. It was a beloved uncle who inspired his medical career-a free-spirited doctor who once took 8-year-old Kanti with him on house calls, riding atop a camel.
US cancer patients still plagued by undertreated pain
June 1st 2008The truth about cancer pain hurts: Many oncology patients still suffer needlessly from unrelieved pain. This quandary is underscored by two disconcerting facts: We have the tools to alleviate upwards of 90% of cancer pain, and the problem was identified decades ago.
A surgeon brings cancer care to Harlem
April 1st 2008Dr. Harold Freeman is a soft-spoken man with strong-held opinions. He grew up in our nation’s capital at a time when restroom doors and drinking fountains radiated the ugly messages of segregation, while African-American churches and schools provided a strong cohesive community. As a youth, he rose above the racial barriers of the time, ultimately forging his anger at racial disparities into his life’s work.
The long and winding road to Houston
March 1st 2008Gabriel N. Hortobagyi, MD, was born in Hungary to a mother who had wanted to be physician. “It was a time and place in which medicine was not a suitable profession for a woman, yet I think my mother’s subliminal messages worked on me,” he said in an interview with Oncology News International.
Making faster, better, more cost-effective clinical trials
February 1st 2008Over the past few years, the number of new cancer drugs approved by FDA has been dwindling. Critics generally cite exorbitant costs, lack of accrual to trials, conflicts of interest, and government regulations as the primary reasons for the dearth of new molecular compounds.
Inaccurate lab reports put breast cancer patients at risk
February 1st 2008Studies show that thousands of women may be receiving the wrong breast cancer treatment because of faulty laboratory reports. More disturbing, this trend was identified years ago. A 2006 study led by Genentech found 14% to 16% of HER2 tests were false positive and 18% to 23% were false negative.